Sesen Bio's EBIT is $49M, below the Healthcare sector average of $23B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2025
Trailing 12 months ending Sep 30, 2025
Sesen Bio (SESN) currently reports a EBIT of $49M as of September 2025. That compares with $-41M in the prior-year period — up 218.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Sesen Bio's EBIT history and peer comparisons.
Sesen Bio's EBIT increased from $-41M to $49M — a 218.0% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Sesen Bio's EBIT of $49M is lower than the Healthcare sector average of $23B. That is roughly 99.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Sesen Bio reported $49M in EBIT as of September 2025. That compares with $-41M in the prior-year period — up 218.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $49M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Sesen Bio, and consider following SESN for alerts when major investors trade the stock.